LIM-domain binding protein 2 was down-regulated by miRNA-96-5p inhibited the proliferation, invasion and metastasis of lung cancer H1299 cells

Chu, Fuying; Xu, Xinxin; Zhang, Yan; Cai, Hua; Peng, Jingjing; Li, Yanan; Zhang, Han; Liu, Hongli; Chen, Xiang

doi:10.1016/j.clinsp.2022.100145

Cited by 5 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NcRNAs have been proven to serve as key modulators that mediate invasion and metastasis in LC. For example, miR-96-5p was found to activate the MAPK signaling pathway by targeting domain-binding protein 2, leading to the repression of invasion and metastasis in LC cells (127). MiR-520a-3p decreased NF-kB p65 levels by targeting AKT1, thereby inactivating the NF-kB pathway and ultimately suppressing cell invasion and metastasis in NSCLC cells (128).…”

Section: Ncrna In Lc Invasion and Metastasismentioning

confidence: 99%

“…Targeting oncogenic ncRNAs represents a highly feasible solution for patients to improve LC interventions. Chu et al showed that miR-96-5p levels were dramatically increased in LC tissues, and its upregulation altered the expression of Bax, MMP9, and Bcl-2 through downregulating domain-binding protein 2, thereby facilitating invasion and proliferation in H1299 cell lines (127). In another study by Lv et al, lncRNA MNX1-AS1 was remarkably increased in LC samples, and its downregulation repressed the proliferation, migration, invasion, and sphere-forming abilities of LC CSCs by activating myosin IG (216).…”

Section: Ncrna In Lc Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications

Liu,

Ding,

Wang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Lung cancer (LC) is a heterogeneous disease with high malignant degree, rapid growth, and early metastasis. The clinical outcomes of LC patients are generally poor due to the insufficient elucidation of pathological mechanisms, low efficiency of detection and assessment methods, and lack of individualized therapeutic strategies. Non-coding RNAs (ncRNAs), including microRNA (miRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA), are endogenous regulators that are widely involved in the modulation of almost all aspects of life activities, from organogenesis and aging to immunity and cancer. They commonly play vital roles in various biological processes by regulating gene expression via their interactions with DNA, RNA, or protein. An increasing amount of studies have demonstrated that ncRNAs are closely correlated with the initiation and development of LC. Their dysregulation promotes the progression of LC via distinct mechanisms, such as influencing protein activity, activating oncogenic signaling pathways, or altering specific gene expression. Furthermore, some ncRNAs present certain clinical values as biomarker candidates and therapeutic targets for LC patients. A complete understanding of their mechanisms in LC progression may be highly beneficial to developing ncRNA-based therapeutics for LC patients. This review mainly focuses on the intricate mechanisms of miRNA, lncRNA, and circRNA involved in LC progression and discuss their underlying applications in LC treatment.

show abstract

Section: Ncrna In Lc Invasion and Metastasismentioning

confidence: 99%

Section: Ncrna In Lc Treatmentmentioning

confidence: 99%

Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications

Liu,

Ding,

Wang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In some tumor cell lines, the level of miRNA-96 is frequently increased, while in some tumor cell lines, it can also be decreasing the level (Table 1). For instance, in lung cancer, Chu et al revealed that LIM-domain binding protein 2 was downregulated by miRNA-96-5p, which prevented lung cancer H1299 cells from proliferating, invasiveness, and metastasizing (Chu et al, 2023). Similarly, Zhang et al Findings show that miR-96 is more expressed in breast cancer tissues and cell lines and can directly influence the expression of RECK to increase cellular proliferation, migration, and invasion, suggesting that miR-96 may be a potential drug target for breast cancer ( Zhang et al, 2014).…”

Section: Cancer and Mirna-96 Expressionmentioning

confidence: 99%

A New Insight of MicroRNA-96 In Human Malignant Disorders and Drug Resistance

2023

QZJ

View full text Add to dashboard Cite

Autumn2023miRNA-96 is a short non-coding RNA molecule which plays an essential function in the regulation of post-transcriptional gene, and play a role in the development of a number of illnesses, such as cancer, depending on the cellular setting, it may function as a tumor suppressor or an oncogene. According to a recent research, miRNA-96 levels has been decreased in gastric cancer, breast cancer, pancreatic cancer, renal cancer and cervical cancer. However, the levels of miRNA-96 in several kinds of cancers are increased, including colorectal, lung, prostate, glioma, osteosarcoma, and hepatocellular carcinoma. The current review aims to offer a summary of miRNA-96's role in the advancement of cancer illnesses and with an emphasis on dysregulated signaling pathways. Based on in vivo, in vitro, and human research, we also go over the function of this miRNA-96 as a cancer biomarker of prognosis and emphasize how it contributes to drug resistance.

show abstract